Pediatrix Q1 net rev $491M, GAAP EPS $0.17, adj EPS $0.23, reaffirms FY adj EBITDA $235-245M

Pediatrix Medical Group, Inc.

2023-Q1 EPS reported $0.17 revenue$491,008,000

Net revenue $491M, up 1.8% YoY; same-unit revenue up 2.0% driven by volume and collections.
GAAP EPS $0.17; adjusted EPS $0.23; prior year adjusted EPS $0.33 (incl $0.07 CARES benefit).
Adjusted EBITDA $40.1M vs $50.7M YoY; FY 2023 guidance reaffirmed at $235-245M.
Cash used in ops $100.6M; total debt $752M; share count decreased due to 2022 buybacks.
No CARES Act revenue recorded in Q1 2023 vs $10.4M in Q1 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pediatrix Medical Group, Inc. reported the three months ended March 31, 2023 results: revenue $491 million, net income $14 million, EPS $0.17 per share.

Period: the three months ended March 31, 2023
Revenue: $491 million
Net income: $14 million
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million.

View on SEC.gov

Browse all earnings releases →

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-016427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.